Borman, P. Et Al. 2014. Subcutaneous (SC) Methotrexate (MTX) is better and well-tolerable than oral MTX in rheumatoid arthritis patients, switched from oral to SC administration due to gastrointestinal side effects. Open Rheumatology Journal , vol.9, no.1 , 18-19.

Borman, P., Demir, G., Kaygısız, F., & Okumuş, M., (2014). Subcutaneous (SC) Methotrexate (MTX) is better and well-tolerable than oral MTX in rheumatoid arthritis patients, switched from oral to SC administration due to gastrointestinal side effects. Open Rheumatology Journal , vol.9, no.1, 18-19.

Borman, Pinar Et Al. "Subcutaneous (SC) Methotrexate (MTX) is better and well-tolerable than oral MTX in rheumatoid arthritis patients, switched from oral to SC administration due to gastrointestinal side effects," Open Rheumatology Journal , vol.9, no.1, 18-19, 2014

Borman, Pinar Et Al. "Subcutaneous (SC) Methotrexate (MTX) is better and well-tolerable than oral MTX in rheumatoid arthritis patients, switched from oral to SC administration due to gastrointestinal side effects." Open Rheumatology Journal , vol.9, no.1, pp.18-19, 2014

Borman, P. Et Al. (2014) . "Subcutaneous (SC) Methotrexate (MTX) is better and well-tolerable than oral MTX in rheumatoid arthritis patients, switched from oral to SC administration due to gastrointestinal side effects." Open Rheumatology Journal , vol.9, no.1, pp.18-19.

@article{article, author={Pinar Borman Et Al. }, title={Subcutaneous (SC) Methotrexate (MTX) is better and well-tolerable than oral MTX in rheumatoid arthritis patients, switched from oral to SC administration due to gastrointestinal side effects}, journal={Open Rheumatology Journal}, year=2014, pages={18-19} }